Header Logo

Connection

AMAN U BUZDAR to Prognosis

Back to Details
This is a "connection" page, showing publications AMAN U BUZDAR has written about Prognosis.
AMAN U BUZDAR
Connection Strength
0.428
Prognosis
  1. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008 Mar 01; 26(7):1059-65.
    View in: PubMed
    Score: 0.022
  2. Update on the management of inflammatory breast cancer. Clin Adv Hematol Oncol. 2006 May; 4(5):344-5.
    View in: PubMed
    Score: 0.020
  3. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002 Jun 22; 359(9324):2131-9.
    View in: PubMed
    Score: 0.015
  4. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060.
    View in: PubMed
    Score: 0.010
  5. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996 Aug; 14(8):2197-205.
    View in: PubMed
    Score: 0.010
  6. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996 Jul; 14(7):2000-11.
    View in: PubMed
    Score: 0.010
  7. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15; 77(12):2503-13.
    View in: PubMed
    Score: 0.010
  8. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015 Apr 16; 17:56.
    View in: PubMed
    Score: 0.009
  9. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med. 1994 Jan 01; 120(1):18-25.
    View in: PubMed
    Score: 0.008
  10. Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study. Breast Cancer Res Treat. 2013 Jul; 140(2):253-62.
    View in: PubMed
    Score: 0.008
  11. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res (Phila). 2012 Feb; 5(2):276-82.
    View in: PubMed
    Score: 0.007
  12. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011 Dec 10; 29(35):4654-61.
    View in: PubMed
    Score: 0.007
  13. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011 Nov 10; 29(32):4273-8.
    View in: PubMed
    Score: 0.007
  14. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011 May 20; 29(15):1956-62.
    View in: PubMed
    Score: 0.007
  15. Predictive algorithms for adjuvant therapy: TransATAC. Steroids. 2011 Jul; 76(8):777-80.
    View in: PubMed
    Score: 0.007
  16. Current status of adjuvant therapy of early breast cancer. Am J Clin Oncol. 1991 Apr; 14(2):101-10.
    View in: PubMed
    Score: 0.007
  17. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011 Mar; 253(3):572-9.
    View in: PubMed
    Score: 0.007
  18. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010 Jun 15; 116(12):2884-9.
    View in: PubMed
    Score: 0.007
  19. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010 Jan 01; 28(1):92-8.
    View in: PubMed
    Score: 0.006
  20. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol. 1989 Apr; 12(2):123-8.
    View in: PubMed
    Score: 0.006
  21. The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy. Cancer. 1989 Mar 01; 63(5):828-35.
    View in: PubMed
    Score: 0.006
  22. Management of locally advanced breast cancer. Am J Clin Oncol. 1988 Oct; 11(5):597-601.
    View in: PubMed
    Score: 0.006
  23. Staging of breast cancer in the neoadjuvant setting. Cancer Res. 2008 Aug 15; 68(16):6477-81.
    View in: PubMed
    Score: 0.006
  24. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83.
    View in: PubMed
    Score: 0.006
  25. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol. 2009 Jan; 135(1):141-8.
    View in: PubMed
    Score: 0.006
  26. Bilateral primary breast cancer in patients treated with adjuvant therapy. Am J Clin Oncol. 1988 Apr; 11(2):114-8.
    View in: PubMed
    Score: 0.006
  27. Recent advances in the hormonal treatment of breast cancer. Curr Probl Surg. 2008 Jan; 45(1):13-55.
    View in: PubMed
    Score: 0.006
  28. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008 Jan 10; 26(2):246-52.
    View in: PubMed
    Score: 0.006
  29. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007 Oct 01; 110(7):1436-44.
    View in: PubMed
    Score: 0.005
  30. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007 May; 18(5):874-80.
    View in: PubMed
    Score: 0.005
  31. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer. 2007 Feb 01; 109(3):496-501.
    View in: PubMed
    Score: 0.005
  32. Progress in inflammatory breast cancer: cause for cautious optimism. J Clin Oncol. 1986 Dec; 4(12):1727-9.
    View in: PubMed
    Score: 0.005
  33. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2006 Sep 15; 107(6):1248-54.
    View in: PubMed
    Score: 0.005
  34. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006 Mar 01; 24(7):1037-44.
    View in: PubMed
    Score: 0.005
  35. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1024s-1030s.
    View in: PubMed
    Score: 0.005
  36. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005 Dec 20; 23(36):9304-11.
    View in: PubMed
    Score: 0.005
  37. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005 Oct 01; 23(28):7098-104.
    View in: PubMed
    Score: 0.005
  38. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005 Sep 15; 104(6):1158-71.
    View in: PubMed
    Score: 0.005
  39. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Cancer. 2005 Jul 15; 104(2):229-35.
    View in: PubMed
    Score: 0.005
  40. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer. 2005 Jun 15; 103(12):2466-72.
    View in: PubMed
    Score: 0.005
  41. Breast cancer. Cancer Treat Rev. 1984 Dec; 11(4):315-9.
    View in: PubMed
    Score: 0.005
  42. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6215-21.
    View in: PubMed
    Score: 0.004
  43. Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer. 2004 Sep 01; 101(5):913-7.
    View in: PubMed
    Score: 0.004
  44. Breast carcinoma in men: a population-based study. Cancer. 2004 Jul 01; 101(1):51-7.
    View in: PubMed
    Score: 0.004
  45. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer. 2004 Feb 01; 100(3):465-9.
    View in: PubMed
    Score: 0.004
  46. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer. 2004 Feb 01; 100(3):499-506.
    View in: PubMed
    Score: 0.004
  47. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004 Feb; 4(6):415-9.
    View in: PubMed
    Score: 0.004
  48. Is breast cancer survival improving? Cancer. 2004 Jan 01; 100(1):44-52.
    View in: PubMed
    Score: 0.004
  49. Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer. Recent Results Cancer Res. 1984; 96:141-7.
    View in: PubMed
    Score: 0.004
  50. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biol Blood Marrow Transplant. 2003 May; 9(5):330-40.
    View in: PubMed
    Score: 0.004
  51. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1225-33.
    View in: PubMed
    Score: 0.004
  52. Peptichemio versus melphalan (L-PAM) in advanced breast cancer. Cancer. 1982 May 01; 49(9):1767-70.
    View in: PubMed
    Score: 0.004
  53. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat. 1982; 2(2):163-9.
    View in: PubMed
    Score: 0.004
  54. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer. 2001 Nov 15; 92(10):2523-8.
    View in: PubMed
    Score: 0.004
  55. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001 Nov 01; 92(9):2247-58.
    View in: PubMed
    Score: 0.004
  56. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol. 2001 Apr 15; 19(8):2240-6.
    View in: PubMed
    Score: 0.003
  57. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg. 2001 Apr; 181(4):313-8.
    View in: PubMed
    Score: 0.003
  58. Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Ann Surg Oncol. 2000 Sep; 7(8):581-7.
    View in: PubMed
    Score: 0.003
  59. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000 Aug; 18(15):2817-27.
    View in: PubMed
    Score: 0.003
  60. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol. 2000 Jul; 7(6):435-40.
    View in: PubMed
    Score: 0.003
  61. Use of prognostic factors in analysis of historical control studies. Cancer Treat Rep. 1980 Feb-Mar; 64(2-3):373-9.
    View in: PubMed
    Score: 0.003
  62. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999 Jul; 230(1):72-8.
    View in: PubMed
    Score: 0.003
  63. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998 Dec; 176(6):502-9.
    View in: PubMed
    Score: 0.003
  64. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. Ann Oncol. 1998 Apr; 9(4):413-8.
    View in: PubMed
    Score: 0.003
  65. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer. 1997 Dec 15; 80(12):2240-9.
    View in: PubMed
    Score: 0.003
  66. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1997 Oct; 15(10):3171-7.
    View in: PubMed
    Score: 0.003
  67. Locally advanced noninflammatory breast cancer. Surg Clin North Am. 1996 Apr; 76(2):393-410.
    View in: PubMed
    Score: 0.002
  68. Aggressive therapy for locoregional recurrence after mastectomy in stage II and III breast cancer patients. Ann Surg Oncol. 1996 Mar; 3(2):162-8.
    View in: PubMed
    Score: 0.002
  69. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer. 1994 Apr 15; 73(8):2157-67.
    View in: PubMed
    Score: 0.002
  70. Combined endocrine and chemotherapy--any true benefits? Breast Cancer Res Treat. 1984; 4(4):251-9.
    View in: PubMed
    Score: 0.002
  71. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol. 1990 Jul; 8(7):1207-16.
    View in: PubMed
    Score: 0.002
  72. Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience. Cancer Chemother Pharmacol. 1990; 27(2):94-100.
    View in: PubMed
    Score: 0.002
  73. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg. 1989 Jan; 124(1):21-5.
    View in: PubMed
    Score: 0.001
  74. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988 Dec 15; 62(12):2507-16.
    View in: PubMed
    Score: 0.001
  75. Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol. 1987 Oct; 10(5):396-403.
    View in: PubMed
    Score: 0.001
  76. Clinical course of breast cancer patients with liver metastases. J Clin Oncol. 1987 May; 5(5):773-82.
    View in: PubMed
    Score: 0.001
  77. Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. Dev Biol Stand. 1986; 58 ( Pt A):357-63.
    View in: PubMed
    Score: 0.001
  78. Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol. 1985 Apr; 8(2):134-41.
    View in: PubMed
    Score: 0.001
  79. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer. 1985 Jan 15; 55(2):341-6.
    View in: PubMed
    Score: 0.001
  80. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol. 1984 Nov; 20(11):1353-61.
    View in: PubMed
    Score: 0.001
  81. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983 Dec; 1(12):776-86.
    View in: PubMed
    Score: 0.001
  82. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 1983 Apr 08; 249(14):1881-6.
    View in: PubMed
    Score: 0.001
  83. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer. Cancer. 1983 Mar 01; 51(5):769-72.
    View in: PubMed
    Score: 0.001
  84. Multimodal treatment of locoregionally advanced breast cancer. Cancer. 1983 Mar 01; 51(5):763-8.
    View in: PubMed
    Score: 0.001
  85. Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983 Feb; 143(2):237-40.
    View in: PubMed
    Score: 0.001
  86. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer. 1982 Feb 01; 49(3):413-7.
    View in: PubMed
    Score: 0.001
  87. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):775-9.
    View in: PubMed
    Score: 0.001
  88. Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma. Cancer. 1981 Mar 15; 47(6):1369-76.
    View in: PubMed
    Score: 0.001
  89. Estrogen receptor: a prognostic factor in breast cancer. Cancer. 1981 Feb 01; 47(3):554-60.
    View in: PubMed
    Score: 0.001
  90. Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer. 1980 Aug 01; 46(3):438-45.
    View in: PubMed
    Score: 0.001
  91. Knowledge acquisition from historical data: application to breast cancer patients. Bull Cancer. 1980; 67(4):437-45.
    View in: PubMed
    Score: 0.001
  92. Endobronchial metastases in breast carcinoma. West J Med. 1978 Sep; 129(3):177-80.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.